|
|
|
|
|
| Recent Announcements |
|
| Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA |
|
READ MORE |
|
|
|
|
Nano In Cancer 2010 Presentation
Systemic delivery and antitumor activity of siRNA complexed with single walled carbon nanotubes. |
|
| READ MORE |
|
|
|
8th Annual Nanotechnology and Sustainability Venture Forum
|
|
| READ MORE |
|
|
|
|
|
| |
| Recent Announcements |
|
| Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA |
|
|
D. Lynn Kirkpatrick, Michelle Weiss, Olga Gliko, Anton Naumov, and R. Bruce Weisman.
Ensysce Biosciences. Inc., Houston, TX, Rice University, Houston, TX
READ FULL ARTICLE |
|
| Nano In Cancer 2010 Presentation |
|
|
Systemic delivery and antitumor activity of siRNA complexed with single walled carbon nanotubes.
Authors: D. Lynn Kirkpatrick, Michelle K. Weiss, Robert Lemos, Geoffrey Bartholomeusz, Saunab Ghosh, R. Bruce Weisman. Ensysce Biosciences Inc., Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Rice University, Houston, TX.
READ FULL ARTICLE |
|
| Presentation Nov. 10, 2009 |
|
|
READ FULL ARTICLE |
|
| Safety of single-walled carbon nanotubes for delivery of siRNA |
|
D. Lynn Kirkpatrick, Geoffrey Bartholomeusz, Michelle Weiss, Dmitri Tsyboulski, Saunab Ghosh, Anton Naumov, R. Bruce Weisman.
Ensysce Biosciences. Inc., Houston, TX, UT MD Anderson Cancer Center, Houston, TX, Rice University, Houston, TX
READ FULL ARTICLE |
|
| 8th Annual Nanotechnology and Sustainability Venture Forum |
|
Ensysce Biosciences to present at 8th Annual Nanotechnology and Sustainability Venture Forum
READ FULL ARTICLE |
|
| Jan 8, 2009 : "Nanotechnology: The Opportunity for Cancer Treatment" |
|
Bob Gower to give Keynote Speech at Chemical Heritage Society's Joseph Priestly Society Symposium.
READ FULL ARTICLE |
|
| Jan 5, 2009: Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO. |
|
Houston, TX, Jan 5, 2009 - Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside.
READ FULL ARTICLE |
|
|
|
|
|
|
|
